Time course of histological progression in primary biliary cirrhosis

G. Richard Locke, Terry M. Therneau, Jurgen Ludwig, E. Rolland Dickson, Keith Lindor

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Histological staging is used for stratification and assessment of treatment efficacy in therapeutic trials for primary biliary cirrhosis (PBC). Knowledge of the rate of progression of the histological changes would he helpful in the design (duration) and conduct of clinical trials. The histological stages were recorded for liver biopsies performed annually on 222 patients during a randomized, placebo-controlled clinical trial in which therapy with D-penicillamine (DPCA) was shown to be ineffective. These data were analyzed using a Markov model to describe the time course of histological progression in PBC. At study entry, 15 patients were stage I, 56 were stage II, 96 were stage III, and 55 were stage IV. Histological progression was observed after 1 year in 41%, 43%, and 35% of the patients, and after 2 years in 62%, 62%, and 50% of the patients who were stage I, stage II, and stage III at entry, respectively. After 4 years biopsies showed cirrhosis in 31% and 50% of the patients in stage I and stage II at entry, respectively. A minority (20%) of the precirrhotic patients showed histological stability; sustained histological regression was rarely observed (2%). Our data suggest that a majority of patients with PBC will progress histologically within 2 years. The distribution of histological stages over time may be helpful in determining the number of patients and length of time necessary to appreciate a treatment effect on histological progression in clinical trials for PBC.

Original languageEnglish (US)
Pages (from-to)52-56
Number of pages5
JournalHepatology
Volume23
Issue number1
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Biliary Liver Cirrhosis
Clinical Trials
Biopsy
Penicillamine
Fibrosis
Therapeutics
Randomized Controlled Trials
Placebos
Liver

ASJC Scopus subject areas

  • Hepatology

Cite this

Time course of histological progression in primary biliary cirrhosis. / Richard Locke, G.; Therneau, Terry M.; Ludwig, Jurgen; Dickson, E. Rolland; Lindor, Keith.

In: Hepatology, Vol. 23, No. 1, 1996, p. 52-56.

Research output: Contribution to journalArticle

Richard Locke, G, Therneau, TM, Ludwig, J, Dickson, ER & Lindor, K 1996, 'Time course of histological progression in primary biliary cirrhosis', Hepatology, vol. 23, no. 1, pp. 52-56. https://doi.org/10.1053/jhep.1996.v23.pm0008550048
Richard Locke, G. ; Therneau, Terry M. ; Ludwig, Jurgen ; Dickson, E. Rolland ; Lindor, Keith. / Time course of histological progression in primary biliary cirrhosis. In: Hepatology. 1996 ; Vol. 23, No. 1. pp. 52-56.
@article{7aaeae80ec7241f9a650128c1fd335c4,
title = "Time course of histological progression in primary biliary cirrhosis",
abstract = "Histological staging is used for stratification and assessment of treatment efficacy in therapeutic trials for primary biliary cirrhosis (PBC). Knowledge of the rate of progression of the histological changes would he helpful in the design (duration) and conduct of clinical trials. The histological stages were recorded for liver biopsies performed annually on 222 patients during a randomized, placebo-controlled clinical trial in which therapy with D-penicillamine (DPCA) was shown to be ineffective. These data were analyzed using a Markov model to describe the time course of histological progression in PBC. At study entry, 15 patients were stage I, 56 were stage II, 96 were stage III, and 55 were stage IV. Histological progression was observed after 1 year in 41{\%}, 43{\%}, and 35{\%} of the patients, and after 2 years in 62{\%}, 62{\%}, and 50{\%} of the patients who were stage I, stage II, and stage III at entry, respectively. After 4 years biopsies showed cirrhosis in 31{\%} and 50{\%} of the patients in stage I and stage II at entry, respectively. A minority (20{\%}) of the precirrhotic patients showed histological stability; sustained histological regression was rarely observed (2{\%}). Our data suggest that a majority of patients with PBC will progress histologically within 2 years. The distribution of histological stages over time may be helpful in determining the number of patients and length of time necessary to appreciate a treatment effect on histological progression in clinical trials for PBC.",
author = "{Richard Locke}, G. and Therneau, {Terry M.} and Jurgen Ludwig and Dickson, {E. Rolland} and Keith Lindor",
year = "1996",
doi = "10.1053/jhep.1996.v23.pm0008550048",
language = "English (US)",
volume = "23",
pages = "52--56",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Time course of histological progression in primary biliary cirrhosis

AU - Richard Locke, G.

AU - Therneau, Terry M.

AU - Ludwig, Jurgen

AU - Dickson, E. Rolland

AU - Lindor, Keith

PY - 1996

Y1 - 1996

N2 - Histological staging is used for stratification and assessment of treatment efficacy in therapeutic trials for primary biliary cirrhosis (PBC). Knowledge of the rate of progression of the histological changes would he helpful in the design (duration) and conduct of clinical trials. The histological stages were recorded for liver biopsies performed annually on 222 patients during a randomized, placebo-controlled clinical trial in which therapy with D-penicillamine (DPCA) was shown to be ineffective. These data were analyzed using a Markov model to describe the time course of histological progression in PBC. At study entry, 15 patients were stage I, 56 were stage II, 96 were stage III, and 55 were stage IV. Histological progression was observed after 1 year in 41%, 43%, and 35% of the patients, and after 2 years in 62%, 62%, and 50% of the patients who were stage I, stage II, and stage III at entry, respectively. After 4 years biopsies showed cirrhosis in 31% and 50% of the patients in stage I and stage II at entry, respectively. A minority (20%) of the precirrhotic patients showed histological stability; sustained histological regression was rarely observed (2%). Our data suggest that a majority of patients with PBC will progress histologically within 2 years. The distribution of histological stages over time may be helpful in determining the number of patients and length of time necessary to appreciate a treatment effect on histological progression in clinical trials for PBC.

AB - Histological staging is used for stratification and assessment of treatment efficacy in therapeutic trials for primary biliary cirrhosis (PBC). Knowledge of the rate of progression of the histological changes would he helpful in the design (duration) and conduct of clinical trials. The histological stages were recorded for liver biopsies performed annually on 222 patients during a randomized, placebo-controlled clinical trial in which therapy with D-penicillamine (DPCA) was shown to be ineffective. These data were analyzed using a Markov model to describe the time course of histological progression in PBC. At study entry, 15 patients were stage I, 56 were stage II, 96 were stage III, and 55 were stage IV. Histological progression was observed after 1 year in 41%, 43%, and 35% of the patients, and after 2 years in 62%, 62%, and 50% of the patients who were stage I, stage II, and stage III at entry, respectively. After 4 years biopsies showed cirrhosis in 31% and 50% of the patients in stage I and stage II at entry, respectively. A minority (20%) of the precirrhotic patients showed histological stability; sustained histological regression was rarely observed (2%). Our data suggest that a majority of patients with PBC will progress histologically within 2 years. The distribution of histological stages over time may be helpful in determining the number of patients and length of time necessary to appreciate a treatment effect on histological progression in clinical trials for PBC.

UR - http://www.scopus.com/inward/record.url?scp=19144370923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19144370923&partnerID=8YFLogxK

U2 - 10.1053/jhep.1996.v23.pm0008550048

DO - 10.1053/jhep.1996.v23.pm0008550048

M3 - Article

VL - 23

SP - 52

EP - 56

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -